A5084279197- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Long-Term Effects of COVID-19
- HIV-related health complications and treatments
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- Respiratory Support and Mechanisms
- Hemodynamic Monitoring and Therapy
- Syphilis Diagnosis and Treatment
- Bacillus and Francisella bacterial research
- HIV, Drug Use, Sexual Risk
- Poxvirus research and outbreaks
- Bipolar Disorder and Treatment
- Herpesvirus Infections and Treatments
- Electrolyte and hormonal disorders
- Sepsis Diagnosis and Treatment
- COVID-19 Impact on Reproduction
- SARS-CoV-2 detection and testing
University of Pennsylvania
1976-2024
Hospital of the University of Pennsylvania
2019-2024
Pennsylvania Hospital
2023
Medical University of Vienna
2017
Abstract Background Injectable cabotegravir (CAB)/rilpivirine (RPV) is the only combination long-acting (LA) antiretroviral regimen approved for HIV. RPV may not be effective among individuals with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, which has >10% prevalence in many countries. Lenacapavir (LEN) an LA capsid given every 6 months, but been studied other agents. Methods We assembled a case series from 4 US academic medical centers where patients adherence...
BackgroundAntibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit hospitalized patients with pneumonia are limited. Here, we assess the efficacy CCP severely ill, adults pneumonia.MethodsWe performed a control trial (PennCCP2), 80 pneumonia, comparing up to 2 units locally sourced plus standard care versus alone. The primary endpoint was...
To gauge the safety and utility of extended tecovirimat/cidofovir for severe mpox, here we report our experience caring 4 patients with mpox advanced human immunodeficiency virus (HIV) at Hospitals University Pennsylvania during 2022 global outbreak. Three had recurrent courses complicated by superinfections, coinfections insufficient nutrition/housing, requiring tecovirimat (5-16 weeks) cidofovir (1-12 doses) probenecid fluids. At follow-up, undetectable HIV RNA on antiretrovirals, improved...
Abstract Background The first long-acting injectable antiretroviral, cabotegravir/rilpivirine (LA-CAB/RPV), was FDA approved in January 2021 for persons with HIV suppressed on their current regimen. Body mass index (BMI) ≥30 kg/m2 has been identified as a risk factor virologic failure, however data is limited due to small sample sizes. aim of this study evaluate the impact BMI efficacy LA-CAB/RPV real-world setting. Methods A retrospective, multi-center cohort conducted from 22, February 15,...
Background: Injectable cabotegravir (CAB)/rilpivirine (RPV) is the only combination long-acting antiretroviral therapy (LA-ART) regimen approved for people with HIV (PWH). However, RPV not effective among individuals nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, which has a higher than 10% prevalence in many countries. Lenacapavir (LEN) newly-approved capsid given every six months, but been studied LA CAB.Methods: Case series from 4 academic medical centers US (UCSF,...
Abstract Background Emergency Departments (EDs) are important sites for HIV testing. However, there is little guidance on how best to implement testing in the ED. The purpose of this study was evaluate screening practices high-risk individuals presenting an ED absence (ED1) and presence (ED2) established program within same academic hospital. Methods We performed a retrospective chart review all 18 years or older either between January 1, 2016 December 31, 2018. High-risk infection...
Abstract Background SARS-CoV-2 monoclonal antibodies (SMA) have demonstrated efficacy in treatment of early, mild to moderate COVID-19 patients at high risk for progression severe COVID-19. We created an SMA infusion clinic a large, urban academic medical center using both internal and community-based referral mechanisms promote the equitable distribution treatment. Methods Data were analyzed from referrals December 13, 2020 through April 20, 2021. Patient demographics, census-based area...